Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory ...

Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by ...

Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug ...

Obesity is a major global health crisis, especially in the United States, but newer weight-loss drugs like Eli Lilly’s (LLY) Zepbound could offer a long-awaited solution — if they become more ...

Eli Lilly moves to defend FDA's tirzepatide shortage resolution amid criticism over supply issues and compounding pharmacy ...

As expected by many, Eli Lilly And Co (NYSE:LLY) filed a motion to intervene as a defendant in a case between the Outsourcing Facilities Association and FarmaKeio Custom Compounding against the FDA.

It hasn’t been a smooth year for the two pharma giants, but events in the fourth quarter widened the gap between them.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other healthcare ...

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on fierce rival Novo Nordisk’s early lead in the obesity market.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other pharma dividend stocks. The pharmaceutical industry in 2024 faced a relatively quiet ...

Eli Lilly is intervening in a lawsuit filed by a trade group representing compounding pharmacies, aiming to block the FDA's determination that the shortage of its GLP-1 medications, Mounjaro and ...